文献速递系统性红斑狼疮

利妥昔单抗治疗SLE结局的预测与预后因素系统综述

Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
PubMed 文献 · Semin Arthritis Rheum · 2017-05-05

总体证据质量(GRADE)为低至极低,所识别的潜在因素仅具假设生成价值,不足以支持常规临床推荐。

要点

  • 基于RCT的预测因素证据质量极低,因缺乏交互检验、亚组功效不足及不精确。
  • 疾病相关因素(临床表型、基线抗ENA/抗Ro抗体、IL2/21 SNP、B细胞耗竭与重建)显示一定预后价值但证据质量低至极低。
  • 现有预后因素研究为假设生成性,不能用于常规临床实践的具体推荐。

核心结论

  • 截至当前,探讨RTX治疗SLE预后因素的研究为假设生成性,不能为常规临床实践提供具体推荐。
  • 已识别若干潜在预测/预后因素,需验证其RTX应答特异性以支持个体化用药。

研究设计与样本

  • 纳入成人及儿童SLE患者,RCT用于评估差异治疗效应的预测因素,队列研究用于评估RTX治疗的潜在预后因素。
  • 方法学质量分别采用Cochrane协作网偏倚风险工具(RCT)和预后研究质量工具QUIPS(队列研究)评估。
  • 采用GRADE框架进行最佳证据合成。

主要发现

  • 总体证据质量(QoE)按GRADE框架为低至极低。
  • 基于RCT分析社会人口学变量的预测因素QoE评为极低,原因包括缺乏交互检验、亚组分析功效有限、研究局限性及不精确性。
  • 疾病相关因素包括临床表型和严重程度、基线抗ENA抗体和抗Ro抗体、白细胞介素(IL)2/21单核苷酸多态性(SNP),以及RTX后完全B细胞耗竭和较早B细胞重建,显示一定预后价值证据。
  • 上述疾病相关因素的QoE评为低至极低,原因包括研究处于早期探索阶段、多数研究对混杂因素调整不足、高偏倚风险、不一致性和不精确性。

关键数值与推荐

  • 总体证据质量(GRADE)为低至极低。
  • 基于RCT的社会人口学预测因素证据质量评为极低。
  • 疾病相关预后因素证据质量评为低至极低。

临床怎么用

  • 现有证据不足以支持将任何预测或预后因素用于常规临床实践以指导RTX治疗决策。
  • 所识别因素需进一步验证其RTX应答特异性后方可用于个体化使用RTX。

局限性

  • 纳入研究多为早期探索性分析,多数对混杂因素调整不足。
  • RCT亚组分析缺乏交互检验且功效有限,导致预测因素证据不精确。
  • 总体证据存在高偏倚风险、不一致性和不精确性,GRADE证据质量低至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical outcomes following rituximab (RTX) treatment in patients with systemic lupus erythematosus (SLE) is highly variable. We aimed to identify predictive and prognostic factors associated with RTX therapy outcomes in patients with SLE. METHODS: Studies in adults and paediatric patients with SLE were included. We included randomized clinical trials (RCTs) for predictors of differential treatment effect and cohort studies for potential prognostic factors in patients treated with RTX (global clinical, cutaneous and renal either response or relapse, and side effects). Methodological quality was assessed using Cochrane Collaboration Risk of Bias tool and the Quality In Prognosis Studies Tool (QUIPS) for RCTs and cohort studies, respectively. The quality of subgroup analyses testing predictors of differential treatment response was also evaluated. A best evidence synthesis was performed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. RESULTS: Sixteen articles were included (3 from 2 RCTs and 13 from 6 cohort studies). The overall quality of evidence (QoE) was low to very low (GRADE framework). QoE for predictive factors based on RCTs analysing sociodemographic variables, was rated very low due to the lack of interaction tests, limited power of subgroup analyses, study limitations, and imprecisions. Disease-related factors including clinical phenotype and severity, baseline anti-ENA antibodies and anti-Ro antibodies, interleukin (IL) 2/21 single nucleotide polymorphism (SNP), as well as post-RTX complete B-cell depletion and earlier B-cell repopulation showed some evidence for prognostic value, but were rated low to very low QoE because of early phase of investigation (exploratory analysis), insufficient adjustment for confounding in most studies, high risk of bias, inconsistency, and imprecisions. CONCLUSIONS: To date, studies addressing prognostic factors are hypothesis generating and cannot be used to make any specific recommendations for routine clinical practice. A number of potential predictors/prognostic factors were identified, which require to be validated as being specific for response to RTX therapy and to enable more personalised use of this agent.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Pirone C, Mendoza-Pinto C, van der Windt DA, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017. PMID: 28602359. doi:10.1016/j.semarthrit.2017.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。